Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/QCO.0000000000000662 http://scihub22266oqcxt.onion/10.1097/QCO.0000000000000662 32657965!ä!32657965 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Infect+Dis 2020 ; 33 (4): 290-297 Nephropedia Template TP {{tp|p=32657965|t=2020. Aspergillus fumigatus and pan-azole resistance: who should be concerned?|pdf=|usr=}}{{32657965}} gab.com Text Aspergillus fumigatus and pan-azole resistance: who should be concerned JO: Curr Opin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32657965 #FOAvip PURPOSE OF REVIEW: Although clinical outcomes in the treatment of aspergillosis have markedly improved with the availability of newer triazoles, the development of resistance to these antifungals, especially in Aspergillus fumigatus, is a growing concern. The purpose of this review is to provide an update on azole resistance mechanisms and their epidemiology in A. fumigatus, the clinical implications of azole resistance, and to discuss future treatment options against azole-resistant aspergillosis. RECENT FINDINGS: Resistance may develop through either patient or environmental azole exposure. Environmental exposure is the most prevalent means of resistance development, and these isolates can cause disease in various at-risk groups, which now include those with influenza, and potentially COVID-19. Although current treatment options are limited, newer therapies are in clinical development. These include agents with novel mechanisms of action which have in vitro and in vivo activity against azole-resistant A. fumigatus. SUMMARY: Azole-resistant A. fumigatus is an emerging threat that hampers our ability to successfully treat patients with aspergillosis. Certain geographic regions and patient populations appear to be at increased risk for this pathogen. As new patient groups are increasingly recognized to be at increased risk for invasive aspergillosis, studies to define the epidemiology and management of azole-resistant A. fumigatus are critically needed. While treatment options are currently limited, new agents under clinical development may offer hope. Twit Text FOAVip Aspergillus fumigatus and pan-azole resistance: who should be concerned ????Curr Opin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32657965 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32657965 #FOAvip English Wikipedia <ref>{{Cite pmid|32657965}}</ref> Aspergillus fumigatus and pan-azole resistance: who should be concerned? #MMPMID32657965 Wiederhold NP; Verweij PE Curr Opin Infect Dis 2020[Aug]; 33 (4): 290-297 PMID32657965show ga PURPOSE OF REVIEW: Although clinical outcomes in the treatment of aspergillosis have markedly improved with the availability of newer triazoles, the development of resistance to these antifungals, especially in Aspergillus fumigatus, is a growing concern. The purpose of this review is to provide an update on azole resistance mechanisms and their epidemiology in A. fumigatus, the clinical implications of azole resistance, and to discuss future treatment options against azole-resistant aspergillosis. RECENT FINDINGS: Resistance may develop through either patient or environmental azole exposure. Environmental exposure is the most prevalent means of resistance development, and these isolates can cause disease in various at-risk groups, which now include those with influenza, and potentially COVID-19. Although current treatment options are limited, newer therapies are in clinical development. These include agents with novel mechanisms of action which have in vitro and in vivo activity against azole-resistant A. fumigatus. SUMMARY: Azole-resistant A. fumigatus is an emerging threat that hampers our ability to successfully treat patients with aspergillosis. Certain geographic regions and patient populations appear to be at increased risk for this pathogen. As new patient groups are increasingly recognized to be at increased risk for invasive aspergillosis, studies to define the epidemiology and management of azole-resistant A. fumigatus are critically needed. While treatment options are currently limited, new agents under clinical development may offer hope. |Antifungal Agents/*pharmacology/therapeutic use[MESH] |Aspergillosis/drug therapy/*immunology/microbiology[MESH] |Aspergillus fumigatus/drug effects/*immunology[MESH] |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/*immunology[MESH] |Drug Resistance, Multiple, Fungal/*immunology[MESH] |Environmental Exposure[MESH] |Humans[MESH] |Immunocompromised Host/immunology[MESH] |Microbial Sensitivity Tests[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology[MESH] |SARS-CoV-2[MESH]Aspergillus fumigatus and pan-azole resistance: who should be concerne(epmc).pdf DeepDyve Pubget Overpricing